Annexon, Inc. (ANNX)

Several events have impacted Annexon's stock price over the past six months. Annexon reported better-than-expected Q1 2026 results, with an EPS of $(0.23). Wall Street Zen upgraded Annexon from a "sell" to a "hold" rating. Investors are focused on a catalyst calendar for 2026, including topline Phase 3 ARCHER II data for vonaprument, a BLA submission for tanruprubart, and proof-of-concept data for ANX1502. A proposed increase in authorized common shares signals potential dilution. The company reported $225.0 million in cash, expected to fund operations into the second half of 2027. The stock's 52-week range extends from $1.60 to $7.18, with a closing price of $5.52 as of May 7, 2026.

There is no specific data or indication of demand seasonality for Annexon, Inc.'s products or services. As a clinical-stage biopharmaceutical company, its focus is on drug development and regulatory approvals rather than commercial sales.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for classical complement-mediated disorders. The company's approach involves inhibiting C1q to prevent immune-mediated damage. Its product candidates include Tanruprubart (ANX005) in Phase 3 trials for Guillain-Barré syndrome, Vonaprument (ANX007) in Phase 3 for geographic atrophy, ANX1502 in Phase 1 for autoimmune indications, and ANX009 in Phase 1 for lupus nephritis.

Annexon, Inc. is headquartered in Brisbane, California, United States. Its clinical development programs include sites in North America, Europe, and Asia.

Annexon's brand reputation appears cautiously positive, driven by clinical trial progress and analyst sentiment. The company has a consensus rating of "Moderate Buy" with an average price target of $17.00. Positive topline results from trials for ANX005 and ANX007 have contributed positively. However, a "sell" rating from Weiss Ratings and concerns about potential dilution could affect reputation.

Annexon, Inc. has significant institutional ownership, with 184 institutional owners holding approximately 85.32% of the stock. Major institutional owners include Fmr Llc, Redmile Group, LLC, and BlackRock, Inc. Annexon insiders hold about 17.49% of the stock. Bain Capital Life Sciences Investors LLC is the largest individual shareholder, owning 11.10 million shares.